Clinical Trials Browser

fluzoparib × Breast × 90 days × Clear all

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

Phase 2 Not yet recruiting

Breast Neoplasms